Berstad K, Berstad A
Gastroenterologisk seksjon, Haukeland Sykehus, Bergen.
Tidsskr Nor Laegeforen. 1994 Mar 20;114(8):932-4.
The last three years of research on treatment of Helicobacter pylori infection support the recommendations made by the Working Party, World Congress of Gastroenterology 1990. Meta-analysis shows a noteworthy difference between the recommended regimens favouring the combination of bismuth, metronidazole and tetracycline. No regimen without bismuth has been shown to have a sustained Helicobacter pylori eradication rate exceeding 90%, nor has any alternative regimen been shown convincingly to stem the adverse effects without loss of efficacy. No serious adverse effects have been reported after following the current recommendation of bismuth medication. The highest reported Helicobacter pylori eradication rate according to "intention to treat" approximates 90%, which was obtained using bismuth subnitrate, metronidazole, and oxytetracycline.
过去三年对幽门螺杆菌感染治疗的研究支持了1990年世界胃肠病学大会工作小组提出的建议。荟萃分析表明,推荐方案之间存在显著差异,铋剂、甲硝唑和四环素联合方案更具优势。没有铋剂的方案尚未显示出能使幽门螺杆菌根除率持续超过90%,也没有任何替代方案能令人信服地在不损失疗效的情况下阻止不良反应。按照目前铋剂用药的建议,尚未报告有严重不良反应。根据“意向性治疗”原则报告的最高幽门螺杆菌根除率约为90%,这是使用次硝酸铋、甲硝唑和土霉素获得的。